Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 extension study in participants continuing treatment from prior Taiho trials
2024-516293-29-01Phase 2Authorised
- Sponsor
- Taiho Oncology
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of inqovi in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by Taiho Oncology. Planned start Mar 2022; status: authorised.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-516293-29-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516293-29-01.